News
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
RÉSULTATS ANNUELS 2023/2024 - HRS IDÉALEMENT POSITIONNÉ POUR L'AVENIR : FIN DU CYCLE D'INVESTISSEMENTS MAJEURS ET ACCÉLÉRATION DU DÉVELOPPEMENT INTERNATIONAL
HRS présente ses résultats annuels 2023/2024, marquant la fin d'un cycle d'investissements majeurs et l'accélération du développement international. Chiffre d'affaires en baisse, EBITDA conforme, rebond attendu en 2024/2025 -
COMMUNIQUÉ DE PRESSE
ANNUAL RESULTS 2023/2024 - HRS IDEALLY POSITIONED FOR THE FUTURE: COMPLETION OF MAJOR INVESTMENT CYCLE AND ACCELERATING INTERNATIONAL EXPANSION
HRS presents annual results 2023/2024: completion of major investment cycle, accelerating international expansion. R&D investments doubled, EBITDA in line with expectations, order book of €47 million. HRS positioned for future growth -
COMMUNIQUÉ DE PRESSE
Laxxon Medical to Attend CPHI Milan 2024, Showcasing the cGMP Printing Technology at Adare Pharma Solution’s Facility in Pessano, Italy
Laxxon Medical to showcase cGMP Printing Technology at CPHI Milan 2024, unveiling innovative oral drug delivery systems through SPID® Technology -
-
COMMUNIQUÉ DE PRESSE
SCOR announces that it has entered into exclusive negotiations with the Albin Michel group for the sale of the Humensis group
SCOR enters exclusive negotiations with Albin Michel group for the sale of Humensis, a major publishing group in France, to preserve its brands and influence in the intellectual ecosystem -
